A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentki, których ogólny stan zdrowia pozwala na udział w badaniu (typowe dla większości terapii antyrakowych).
- •U pacjentek musi być widoczna zmiana nowotworowa, którą można zmierzyć za pomocą badań obrazowych (np. tomografii komputerowej lub rezonansu magnetycznego).
- •Pacjentki muszą mieć zdiagnozowany pewien rodzaj raka jajnika, jajowodu lub otrzewnej, który jest agresywnie dzielącym się typem.
- •Pacjentki muszą zakończyć wcześniejsze leczenie zgodnie z określonymi terminami.
✗ Disqualifies
- •Pacjentki z pewnymi rodzajami raka jajnika (np. śluzowym, jasnokomórkowym, mięsakowatym) lub z łagodnymi zmianami.
- •Pacjentki z innymi poważnymi schorzeniami, które mogłyby przeszkodzić w udziale w badaniu lub w leczeniu.
- •Pacjentki, które wcześniej były leczone lekami skierowanymi na określony typ receptora (FRα) w komórkach rakowych.
- •Pacjentki po rozległym leczeniu promieniami, które objęło ponad 20% szpiku kostnego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (21)
Start Los Angeles /ID# 281533
Los Angeles, United States
University of Colorado Hospital- Aurora /ID# 278232
Aurora, United States
University Of Minnesota /ID# 277850
Minneapolis, United States
Holy Name Medical Center /ID# 279017
Teaneck, United States
SUNY Upstate Medical University - Syracuse /ID# 277305
Syracuse, United States
University of Cincinnati Medical Center. /ID# 278925
Cincinnati, United States
University Hospitals Cleveland Medical Center /ID# 279601
Cleveland, United States
OU Health - Stephenson Cancer Center /ID# 277656
Oklahoma City, United States
Providence Portland Medical Center /ID# 277727
Portland, United States
Women & Infants Hospital /ID# 277930
Providence, United States
SCRI Oncology Partners /ID# 279733
Nashville, United States
Texas Oncology-Austin North /ID# 279958
Austin, United States
Next Virginia /ID# 279684
Fairfax, United States
Rabin Medical Center /ID# 279142
Petah Tikva, Israel
The Chaim Sheba Medical Center /ID# 275997
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center /ID# 275852
Tel Aviv, Israel
Rambam Health Care Campus- Haifa /ID# 276004
Haifa, Israel
Shaare Zedek Medical Center /ID# 275854
Jerusalem, Israel
Hyogo Cancer Center /ID# 276940
Akashi-shi, Japan
National Cancer Center Hospital /ID# 276715
Chuo-Ku, Japan
The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 276711
Koto-ku, Japan
Trial contact
ABBVIE CALL CENTER
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.